ライフサイエンスコーパス: platelet aggregation

1 ibited thrombin-, ADP-, and collagen-induced platelet aggregation.

2 leads to potent and reversible inhibition of platelet aggregation.

3 Inhibition of miR-126 in mice reduced platelet aggregation.

4 elet inhibition was monitored by ADP-induced platelet aggregation.

5 activating factor (PAF) and thrombin-induced platelet aggregation.

6 ing its prothrombotic activity and promoting platelet aggregation.

7 vel alphaIIbbeta3 antagonists, which inhibit platelet aggregation.

8 ng in mammals, where ADP plays a key role in platelet aggregation.

9 s an important signaling molecule regulating platelet aggregation.

10 ts of histones and decreases histone-induced platelet aggregation.

11 resulted in defective ITAM receptor-mediated platelet aggregation.

12 release of ATP and fibrinogen, resulting in platelet aggregation.

13 sphodiesterase inhibition, strongly impaired platelet aggregation.

14 ation is distinct from purine involvement in platelet aggregation.

15 h platelet TLR4 and promotes agonist-induced platelet aggregation.

16 ecretion, and impaired fibrin generation and platelet aggregation.

17 le antithrombotic activity via inhibition of platelet aggregation.

18 d platelet activation, factor secretion, and platelet aggregation.

19 S13-mediated proteolysis of VWF and promoted platelet aggregation.

20 ne proteases, contributes to coagulation and platelet aggregation.

21 R4 gene (F2RL3) associated with PAR4-induced platelet aggregation.

22 receptor for, e.g., fibrinogen and mediates platelet aggregation.

23 nule secretion, which is required to augment platelet aggregation.

24 osphate and thromboxane A2 are mandatory for platelet aggregation.

25 IIbbeta3 (GPIIb-IIIa) with fibrinogen during platelet aggregation.

26 uction to complete inhibition of ADP-induced platelet aggregation.

27 nent clinical drug targets for inhibition of platelet aggregation.

28 P), collagen, and rhodocytin (Rhod)-mediated platelet aggregation.

29 rotease-activated receptor 1 (PAR1)-mediated platelet aggregation.

30 to affect thrombin- and cancer-cell-induced platelet aggregation.

31 lant platelet formation in the regulation of platelet aggregation.

32 ts into the cellular and molecular basis for platelet aggregation.

33 c outlet region, contributing to exacerbated platelet aggregation.

34 usly unrecognized abnormality that may favor platelet aggregation.

35 and has no activity in coagulation tests or platelet aggregation.

36 lial cell damage, permeability increase, and platelet aggregation.

37 ceptors (GPCRs), and its activation triggers platelet aggregation.

38 and production of adenosine, an inhibitor of platelet aggregation.

39 face and this abnormality is associated with platelet aggregation.

40 blood and the ability of aspirin to inhibit platelet aggregation.

41 X7 receptors, and inhibited collagen-induced platelet aggregation.

42 and coronary heart disease risk mediated via platelet aggregation.

43 ro-platelet formation, and markedly impaired platelet aggregation.

44 s by shaping the rheological environment for platelet aggregation.

45 mild thrombocytopenia and subtle defects in platelet aggregation.

46 COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation.

47 moderately decreased thrombin-induced human platelet aggregation.

48 reduced nitric oxide-mediated inhibition of platelet aggregation.

49 re bleeding phenotype and complex defects in platelet aggregation.

50 inity to the GPIIb/IIIa receptor involved in platelet aggregation.

51 lbicans can also exert inhibitory effects on platelet aggregation.

52 imary brain tumors via its ability to induce platelet aggregation.

53 mechanism to prevent excessive VWF-mediated platelet aggregation.

54 ion of thrombi rather than the prevention of platelet aggregation.

55 nflammation, cell adhesion, vessel tone, and platelet aggregation.

56 ng, delta-granule content and secretion, and platelet-aggregation; (2) significant decreases of secre

57 on achieved with 80% proportion PT (residual platelet aggregation 80% PT mix/residual platelet aggreg

58 The percentage restoration of residual platelet aggregation achieved with 80% proportion PT (re

59 actin polymerization after GPIb-IX-mediated platelet aggregation, actin polymerization inhibitors di

60 tide exhibiting both FXa inhibition and anti-platelet aggregation activities, with a low bleeding ris

61 identified with both FXa inhibition and anti-platelet aggregation activities.

62 APT and 2APT-D6 inhibited collagen-dependent platelet aggregation, adhesion, thrombus formation, supe

63 rimary end point of the study, inhibition of platelet aggregation after arachidonic acid 1.5 mmol/L a

64 s of CPT and NPT showed potent inhibition of platelet aggregation after pretreatment with 1 mM GSH, c

65 far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists describ

66 s at all other time points and inhibition of platelet aggregation; an exploratory analysis evaluated

67 ular smooth muscle cell migration assays and platelet aggregation analyses.

68 acks and abolished the enhanced PAR4-induced platelet aggregation and 1,4,5-triphosphate generation a

69 Reduced platelet aggregation and a mild bleeding phenotype have

70 PAF is implicated in platelet aggregation and activation through release of v

71 Platelet aggregation and activation were assessed by agg

72 In both rabbits and humans, platelet aggregation and activation were significantly h

73 tures of platelets but significantly impairs platelet aggregation and adenosine triphosphate secretio

74 m Aedes aegypti, binds collagen and inhibits platelet aggregation and adhesion.

75 hate (cGMP)-mediated signaling and inhibited platelet aggregation and arrest under flow.

76 Willebrand factor (VWF), thereby inhibiting platelet aggregation and arterial thrombosis.

77 as associated with higher PAR4-induced human platelet aggregation and Ca2+ flux, and generated greate

78 Platelet aggregation and calcium mobilization induced by

79 hich has pro-inflammatory effects, increases platelet aggregation and clot strength, and reduces fibr

80 iological functions, including inflammation, platelet aggregation and endothelial cell apoptosis, and

81 lebrand factor-coated microfluidic channels, platelet aggregation and fibrin formation induced by 5B9

82 Rac-1-dependent granule release required for platelet aggregation and hemostasis.

83 ood cell (RBC) transfusion increases in vivo platelet aggregation and inflammation in coronary and no

84 (GPIIb/IIIa) is the key receptor involved in platelet aggregation and is a validated target for thera

85 levels in Ip6k1(-/-) mice, along with slower platelet aggregation and lengthened plasma clotting time

86 efractory to granulocyte CSF, from defective platelet aggregation and myelofibrosis.

87 urs postinfection, had significantly reduced platelet aggregation and NET release.

88 tion, the ability of aortic rings to inhibit platelet aggregation and plasma prostacyclin levels were

89 al insight into the underlying mechanisms of platelet aggregation and platelet activation heterogenei

90 CD39-expressing intraepithelial T cells, and platelet aggregation and release of 5-hydroxytryptamine

91 fold increase in inhibitory activity against platelet aggregation and release reactions in response t

92 s before transplantation effectively reduced platelet aggregation and SEC injury, which translated in

93 Primary hemostasis assessment included platelet aggregation and secretion (platelet function ma

94 Thrombin- or collagen-induced platelet aggregation and secretion are increased in TRAF

95 We found that platelet aggregation and secretion in response to 2-meth

96 In contrast, 2-MeSADP- and AYPGKF-induced platelet aggregation and secretion were minimally affect

97 e, patients with cirrhosis and AKI had lower platelet aggregation and secretion, indicative of impair

98 rs are expressed on platelets, which mediate platelet aggregation and shape change.

99 nding to the integrin alphaIIbbeta3 mediates platelet aggregation and spreading on fibrinogen-coated

100 Interestingly, unlike CRP, platelet aggregation and Syk phosphorylation induced by

101 We conclude that ATL regulates neutrophil-platelet aggregation and that platelet-neutrophil intera

102 dent negative feedback mechanism that limits platelet aggregation and thrombotic occlusion.

103 in fluid mechanical conditions that promote platelet aggregation and thrombus formation by increased

104 versibly block substrate binding and inhibit platelet aggregation and thrombus formation in vivo.

105 of G-protein-coupled receptors in supporting platelet aggregation and thrombus formation.

106 platelet reactivity, and in so doing blunts platelet aggregation and thrombus formation.

107 shed the ability to induce heparin-dependent platelet aggregation and tissue factor messenger RNA syn

108 hemostatic potential is important to mediate platelet aggregation and to recruit platelets to the sub

109 for e.g. learning, memory, mood regulation, platelet aggregation and vasoconstriction, but its invol

110 biological processes, including chemotaxis, platelet aggregation, and adaptive immunity.

111 SCA neutrophils display increased neutrophil-platelet aggregation, and CXCR4(hi) neutrophils demonstr

112 tissue edema, augmented leukocyte adhesion, platelet aggregation, and dysregulated vasodilation.

113 c domain and consequent integrin activation, platelet aggregation, and effective hemostasis.

114 thrombocytosis, exaggerated agonist-induced platelet aggregation, and enhanced extra-intestinal thro

115 ted with production of procoagulant factors, platelet aggregation, and facilitation of thrombotic eve

116 of intravascular thrombin activity, reduced platelet aggregation, and improved microvascular perfusi

117 mage, inflammation, vascular reactivity, and platelet aggregation, and improvement in immune function

118 us infection induced neutrophil recruitment, platelet aggregation, and neutrophil extracellular trap

119 hysiological processes such as vasodilation, platelet aggregation, and synaptic plasticity.

120 all shown to inhibit alphaIIbbeta3 dependent platelet aggregation, and these inhibitors became the fo

121 phate, the P2Y1 receptor (P2Y1R) facilitates platelet aggregation, and thus serves as an important an

122 te thrombocytopenia; absent collagen-induced platelet aggregation; and large, fused alpha-granules in

123 ses such as cell adhesion, vasoconstriction, platelet aggregation, angiogenesis, inflammatory gene ex

124 hat platelet number, platelet activation and platelet aggregation are increased in NASH but not in st

125 rs6566765 associations with agonist-induced platelet aggregation are novel.

126 nd convulxin (CVX) (IC50 = 5.7 muM) mediated platelet aggregation as compared to losartan (LOS) (coll

127 th nanomolar potency in the disease-relevant platelet aggregation assay in human plasma.

128 atelet activity was evaluated using the anti-platelet aggregation assay.

129 rmore, we show that NPP1 is unable to induce platelet aggregation at physiologic concentrations repor

130 Platelet aggregation at sites of vascular injury is esse

131 Platelet aggregation at sites of vascular injury is not

132 Platelet aggregation at the site of vascular injury is e

133 may represent a novel mode of regulation of platelet aggregation at the vascular wall.

134 ) were expressed and discovered to attenuate platelet aggregation, ATP secretion, and thromboxane A2

135 otype associated with increased clotting and platelet aggregation attributable to a promoter variant

136 ual platelet aggregation 80% PT mix/residual platelet aggregation baselinex100) significantly decreas

137 METHODS AND RESULTS- We measured ex vivo platelet aggregation before and after dual antiplatelet

138 ) associated with increased thrombin-induced platelet aggregation (beta = 0.70, SE = 0.05).

139 Both agents inhibit human platelet aggregation but preserve clot retraction.

140 Gi signaling; this is insufficient to cause platelet aggregation, but it is enough to predispose pla

141 phil oxidative burst and negatively modulate platelet aggregation by a unique salivary mechanism.

142 Thrombin initiates human platelet aggregation by coordinately activating proteina

143 Among these, active MMP-2 enhances platelet aggregation by favoring the activation of phosp

144 ayed generation of fIIa(MZ) enzyme activity, platelet aggregation by fII(MZ) is similar to fII(WT) Co

145 These data suggest that MRP4 promotes platelet aggregation by modulating the cAMP-protein kina

146 tream of CD36 that are critical in promoting platelet aggregation by oxLDL.

147 displayed enhanced inhibition of ADP-induced platelet aggregation by the nitric oxide donor sodium ni

148 The attenuation of platelet aggregation by the phosphodiesterase inhibitor

149 adaptor protein that regulates the extent of platelet aggregation by two mechanisms.

150 t S. aureus lipoteichoic acid (LTA) inhibits platelet aggregation caused by physiological agonists an

151 stin recruitment triggered greater levels of platelet aggregation compared with the canonical PAR4 ag

152 PEL-negative individuals showed an impaired platelet aggregation, confirming a role for ABCC4 in pla

153 n expression in primary brain tumors induces platelet aggregation, correlates with hypercoagulability

154 s reports have shown that rhodocytin-induced platelet aggregation depends on secondary mediators such

155 ver, flavocetin-A inhibited collagen-induced platelet aggregation even after GPIb was blocked with ot

156 PGN induced platelet aggregation, expression of the activated form o

157 wed a significant reduction in PAR4-mediated platelet aggregation, fibrinogen binding, and P-selectin

158 an platelets or its deletion in mice reduces platelet aggregation, fibrinogen binding, granule secret

159 This study sought to assess inhibition of platelet aggregation following subcutaneous administrati

160 ions stimulated by a range of agonists, with platelet aggregation, granule secretion, adhesion and sp

161 We have previously shown that platelet aggregation has higher heritability in African

162 did not suffer from bleeding and have normal platelet aggregation; however, their platelets mimicked

163 tiple mosquito salivary components mediating platelet aggregation (i.e., Aegyptin, apyrase, D7) repre

164 aIIbbeta3 and ability to inhibit ADP-induced platelet aggregation (IC50) showed that two designed lig

165 orted in human blood, but it could stimulate platelet aggregation if localized at low nanomolar conce

166 effect of the VWF C4 domain for VWF-mediated platelet aggregation in a shear-dependent manner and pro

167 r, a genome-wide association study (GWAS) of platelet aggregation in African Americans has not been r

168 In this first GWAS of agonist-induced platelet aggregation in African Americans, we discovered

169 s: This study compared whole-blood impedance platelet aggregation in children with clinically diagnos

170 We investigate platelet aggregation in coronary-sized arteries using bo

171 Integrin activation and platelet aggregation in mice whose platelets express onl

172 We measured platelet aggregation in response to arachidonic acid, AD

173 occurrence of bleeding events and decreased platelet aggregation in response to collagen in platelet

174 y effect on resting platelets, cLDL enhanced platelet aggregation in response to different agonists.

175 ed a genome-wide association study (GWAS) of platelet aggregation in response to full-length thrombin

176 Platelet aggregation in response to primary human gliobl

177 ular integrity; this function is mediated by platelet aggregation in response to recognition of the e

178 as an important function preventing maternal platelet aggregation in response to the early developing

179 iminished neutrophil adhesion and neutrophil-platelet aggregation in SCD mice, thereby improving bloo

180 GPVI-Fc reduced plaque-triggered platelet aggregation in static blood by 51%, BLO8-1 by 8

181 The relative inhibition of platelet aggregation in the chewing vs the standard grou

182 ulting in spatially confined and exacerbated platelet aggregation in the stenosis outlet region.

183 itions in a stenotic artery, showed enhanced platelet aggregation in the stenotic outlet region at 60

184 wed by the luminal release of VWF fibers and platelet aggregation in tumor microvessels.

185 is enhanced, with a concomitant increase in platelet aggregation in vitro and a reduced duration of

186 were able to inhibit both thrombin-triggered platelet aggregation in vitro and clot consolidation in

187 and selective COX-1 inhibitors that affected platelet aggregation in vitro through the inhibition of

188 uman HIT IgG-induced platelet activation and platelet aggregation in vitro, and thrombus progression

189 h plasma from Fib(AEK) mice supported normal platelet aggregation in vitro, highlighting that fibrino

190 osquitoes failed to inhibit collagen-induced platelet aggregation in vitro.

191 coronary arteries and reciprocally regulated platelet aggregation in washed human platelets.

192 ave developed a novel flow cytometry test of platelet aggregation, in which 10- to 25-fold lower plat

193 xamination of mice lacking integrin-mediated platelet aggregation indicated that platelet aggregation

194 al cells (ECs) showed enhanced inhibition of platelet aggregation induced by adenosine 5'-diphosphate

195 el with a Ki value of 9.02 muM and inhibited platelet aggregation induced by ADP and U46619 in a dose

196 15 R-PGD(2) inhibited human platelet aggregation induced by the thromboxane receptor

197 in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferati

198 times as well as reduced thrombus formation, platelet aggregation, inflammation, and organ damage dur

199 ing dose is feasible, and it does not hinder platelet aggregation inhibition in patients with acute c

200 ding further support for the hypothesis that platelet aggregation inhibition is a vital salivary func

201 Aegyptin did not affect salivary ADP-induced platelet aggregation inhibition or disturb anticlotting

202 ) and 3 antithrombotic/anticoagulant agents (platelet aggregation inhibitors excluding heparin, direc

203 erapy and, at times, therapy with additional platelet aggregation inhibitors.

204 This also can be useful for the design of platelet-aggregation-inspired engineering solutions.

205 Platelet aggregation, integrin alphaIIbbeta3 activation,

206 lor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-e

207 ogrel therapy, device-reported inhibition of platelet aggregation (IPA) trended lower in nonsmokers t

208 Indeed, excessive platelet aggregation is associated with myocardial infar

209 0.05).Conclusions: The finding of increased platelet aggregation is consistent with endothelial dama

210 s whereas Glanzmann thrombasthenia, in which platelet aggregation is reduced, is a bleeding syndrome.

211 In particular, platelet aggregation is routinely measured in an aggrego

212 Adenosine diphosphate (ADP)-mediated platelet aggregation is signaled through two distinct G

213 Genetic attenuation of maternal platelet aggregation is similarly ineffective.

214 atelets and released upon tumor cell-induced platelet aggregation, leading to the production of LPA.

215 Further, we couple the calibrated platelet aggregation model with a tissue-factor/contact

216 gh shear rates (PFA), and ristocetin-induced platelet aggregation (Multiplate) before and after desmo

217 Morphine delayed the maximal inhibition of platelet aggregation on average by 2 h (n = 24; p < 0.00

218 The percentage of platelet aggregation or activation induced by collagen w

219 duce a productive functional response, be it platelet aggregation or leukocyte extravasation.

220 PT or 2APT-D6 led to the inhibition of mouse platelet aggregation, oxygen radical output, and thrombu

221 Six SNPs were significantly associated with platelet aggregation (P<5x10(-8)) in the discovery sampl

222 egometry (11.6% relative increase in maximal platelet aggregation, p = 0.004; 10.8% increase in resid

223 ation, p = 0.004; 10.8% increase in residual platelet aggregation, p = 0.005) and vasodilator-stimula

224 ggregation, p = 0.04, and 12.7% for residual platelet aggregation, p = 0.02) but not with collagen or

225 ide (relative increases of 11.7% for maximal platelet aggregation, p = 0.04, and 12.7% for residual p

226 pathways, the anticoagulant pathway and the platelet aggregation pathway.

227 One mystery in the mechanism of platelet aggregation pertains to how resting platelets i

228 The fact that nitroxyl (HNO) reduces platelet aggregation, preconditions against myocardial i

229 re drug targets, but the role of thrombin in platelet aggregation remains largely unexplored in large

230 blood pressure regulation and inhibition of platelet aggregation require sGC activation by NO.

231 DSS treatment also enhanced the platelet aggregation response to thrombin and accelerate

232 telets, platelet life span, thrombin-induced platelet aggregation response, and light/dye-induced thr

233 and demonstrated higher collagen-stimulated platelet aggregation responses (p = 0.04) than men.

234 At rest, women had heightened platelet aggregation responses to serotonin (p = 0.007)

235 Although platelet aggregation responses were not affected, a defe

236 Platelet aggregation responses, as well as thrombus form

237 sly in 3 pedigrees with bleeding and reduced platelet aggregation responses.

238 at elevated levels of plasma 5-HT accelerate platelet aggregation resulting in a hypercoagulable stat

239 We found that platelet aggregation, secretion, and spreading were dimi

240 ing array of biological functions, including platelet aggregation, smooth muscle cell proliferation,

241 58), was associated with reduced ADP-induced platelet aggregation (Spearman's rank correlation coeffi

242 mediated platelet aggregation indicated that platelet aggregation stabilizes thrombi that form in the

243 virulent infection, including signatures for platelet aggregation, stronger and prolonged anemia and

244 ssments, transthoracic echocardiography, and platelet aggregation studies at baseline and after 3 men

245 Moreover, platelet aggregation studies showed a higher response to

246 sis exhibited an impaired ability to inhibit platelet aggregation, suggesting that altered HDL proper

247 platelet integrin mechanics and its role in platelet aggregation, suggesting that platelets are phys

248 duce TXA2 generation, but rather accelerated platelet aggregation, suggesting that the role of LIMK1

249 ition, 23 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhi

250 latelet adhesion and clot retraction but not platelet aggregation, supporting the role of these regio

251 tients does not exhibit a full inhibition of platelet aggregation, termed 'aspirin resistance' (AR).

252 When platelet aggregation tests (PATs) were performed with pl

253 CC exposure did not induce platelet aggregation, TF microparticle induction, or TF

254 iovascular system from drugs used to inhibit platelet aggregation, the focus of this article will be

255 letion in mice resulted in modestly enhanced platelet aggregation, the formation of large thrombi and

256 in the inflamed venular microvasculature for platelet aggregation thereby effectively promoting the f

257 C-type lectin-like receptor 2-induced human platelet aggregation, thereby phenocopying the effect of

258 for pathological conditions associated with platelet aggregation/thrombi (e.g., stroke), where vWF l

259 mouse models of sepsis, we observed profound platelet aggregation, thrombin activation, and fibrin cl

260 This interaction results in maternal platelet aggregation, thrombosis of the maternal blood,

261 sis, denudation of the underlying matrix and platelet aggregation, thrombotic microangiopathy, and ne

262 Assays measuring platelet aggregation (thrombus formation) at arterial sh

263 platelet RNA and expression-1 study measured platelet aggregation to arachidonic acid, ADP, protease-

264 albicans exerts a significant attenuation of platelet aggregation to multiple agonists.

265 sults: Children with SDB exhibited increased platelet aggregation to TRAP (thrombin receptor-activati

266 L5 enhanced adenosine diphosphate-stimulated platelet aggregation twofold more than did L1 and induce

267 ciated AKT2 regulates heterotypic neutrophil-platelet aggregation under shear conditions.

268 odies inhibit atherosclerotic plaque-induced platelet aggregation under static and flow conditions mo

269 ns bear the GPVI-binding sites that initiate platelet aggregation upon blood exposure during injuries

270 protein expression by Western blot analysis, platelet aggregation using an aggregometer, and shear st

271 patients with measured on-aspirin treatment platelet aggregation values directly before PCI.

272 gregation receptor-1 (PEAR1) participates in platelet aggregation via sustaining alphaIIbbeta3 activa

273 otein on brain vascular endothelium inducing platelet aggregation via the hydrolysis of Ap3A, whereas

274 Defective platelet aggregation was accompanied by impaired inside-

275 Platelet aggregation was explored through a spectrophoto

276 Residual platelet aggregation was higher 1 to 4 h after morphine

277 Platelet aggregation was measured by impedance aggregome

278 Human atherosclerotic plaque-induced platelet aggregation was measured in anticoagulated bloo

279 Platelet aggregation was measured using multiple electro

280 Platelet aggregation was measured using P2Y12 reaction u

281 ting blood sample was taken, and whole-blood platelet aggregation was measured.Measurements and Main

282 No relevant difference in platelet aggregation was observed between the 2 study ar

283 Residual platelet aggregation was significantly reduced in both a

284 After 48 hours of ticagrelor pretreatment, platelet aggregation was suppressed by approximately 80%

285 s creatine kinase level of 4664, ADP-induced platelet aggregation was undetectable, normalizing after

286 sfusion measurements of maximal and residual platelet aggregation were considered with different agon

287 let adhesion and platelet activation but not platelet aggregation were identified as pivotal for NASH

288 brane oxygenation, plasmatic coagulation and platelet aggregation were impaired due to systemic infla

289 brinogen binding, P-selectin expression, and platelet aggregation were lower on treatment with clopid

290 Endothelial activation and platelet aggregation were normal in PAD4(-/-) mice, as w

291 adenosine diphosphate-, or thrombin-induced platelet aggregation were significantly attenuated in Ty

292 Interestingly, pFn promoted platelet aggregation when linked with fibrin but inhibit

293 rterio-venous shunt model was used to assess platelet aggregation, whereas a healthy rabbit model of

294 ot activate calcium signaling fails to cause platelet aggregation, whereas a peptide that is able to

295 This is distinct from platelet aggregation, which is critical for the maintena

296 , BLO8-1 and 5C4 almost completely inhibited platelet aggregation while preserving platelet adhesion

297 in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of

298 ability and faster and greater inhibition of platelet aggregation with arachidonic acid compared with

299 tegrate the initiation of a thrombus through platelet aggregation with its subsequent viscoelastic re

300 imum amplitude, a follow-up study evaluating platelet aggregation would be instructive.